Dr. Rhonda Bitting, MD

Claim this profile

Durham VA Medical Center, Durham, NC

Studies Prostate Cancer
Studies Colorectal polyposis syndrome
5 reported clinical trials
21 drugs studied

Area of expertise

1

Prostate Cancer

Rhonda Bitting, MD has run 4 trials for Prostate Cancer. Some of their research focus areas include:

Stage IV
CDK12 positive
MLH1 positive
2

Colorectal Polyposis Syndrome

Rhonda Bitting, MD has run 1 trial for Colorectal polyposis syndrome. Some of their research focus areas include:

MLH1 positive
MSH2 positive
MSH6 positive

Affiliated Hospitals

Image of trial facility.

Durham VA Medical Center, Durham, NC

Image of trial facility.

Durham VA Medical Center

Clinical Trials Rhonda Bitting, MD is currently running

Image of trial facility.

High Dose Testosterone

for Prostate Cancer

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis

Recruiting

3 awards

Phase 2

Image of trial facility.

Carboplatin vs Olaparib

for Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.

Recruiting

1 award

Phase 2

More about Rhonda Bitting, MD

Clinical Trial Related

5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Rhonda Bitting, MD has experience with

  • Pembrolizumab
  • High Dose Testosterone
  • Cabozantinib
  • Ipilimumab
  • Nivolumab
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Rhonda Bitting, MD specialize in?

Is Rhonda Bitting, MD currently recruiting for clinical trials?

Are there any treatments that Rhonda Bitting, MD has studied deeply?

What is the best way to schedule an appointment with Rhonda Bitting, MD?

What is the office address of Rhonda Bitting, MD?

Is there any support for travel costs?